News

Probiodrug and Crossbeta Extend Alzheimer’s Biomarker Partnership

Probiodrug and Crossbeta Biosciences are extending a partnership that Probiodrug believes will help it continue developing a potential Alzheimer’s therapy. Under the partnership, established in 2016, the companies are using a proprietary Crossbeta technology to try to create biomarkers specific to Alzheimer’s as opposed to   neurodegenerative diseases in general.